SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

CEO Angelos Stergious early anniversary LinkedIn post has traders speculating that major news may be near, including a REGAL trial update or a possible buyout; skeptics see it as a routine anniversary message, not a confirmed signal. Discussion centers on the blinded Phase 3 REGAL trial nearing its final-analysis trigger, with the timing and outcome still uncertain.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is drawing attention ahead of its Q3 earnings report, with traders weighing mixed options positioning and bracing for an event-driven move. Discussion centers on whether pricing and vehicle mix can offset weaker sales and steep declines in EV demand.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are drawing attention amid a steep post-IPO selloff, with traders pointing to newly unlocked shares, insider selling, and an analyst target cut as sources of pressure, alongside concerns about OpenAI customer concentration and the companys ability to scale. Bears expect more downside, while bulls argue the decline has left the AI-chip maker oversold and emphasize its technology and long-term potential.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Interim ARO-MAPT results showing substantial tau reduction after subcutaneous dosing have renewed attention on Arrowheads potential to deliver RNAi therapies across the blood-brain barrier. Many traders view the data as important validation of the platform, while others are frustrated by the muted share-price reaction and note that the results are early biomarker data, not evidence of clinical benefit.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

United is drawing attention for CEO Scott Kirbys comments backing a near-100% inheritance tax, which have prompted some traders to call for a boycott or selloff while others dismiss the remarks as separate from the stock. The debate is unfolding ahead of quarterly results, with traders also weighing the recent share-price pullback, fuel costs and whether demand and guidance can support earnings.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is under pressure amid a broader AI-infrastructure selloff, with traders focused on its heavy debt, financing costs and the risk that capital needs could outpace returns. Bears warn of dilution or distress, while bulls point to AI-compute demand, contracted backlog and dip buying as reasons the business could withstand the strain.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs steep slide to fresh lows is being tied by traders to weakening Trump-related political sentiment and the approaching midterms, with some also pointing to Truth Social engagement and the companys limited operating business. The discussion is overwhelmingly bearish, though a few traders view the decline as a potential entry point or rebound setup.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons rally is drawing attention after Morgan Stanley named it a top pick and raised its outlook, citing accelerating AWS growth and AI-related demand. Traders welcomed the upgrade, while debating whether the jump can hold ahead of earnings and amid concerns about heavy capital spending.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Deltas quarterly earnings miss and reduced full-year outlook, driven by sharply higher fuel costs, are the main focus. Traders are split over whether strong travel and premium demand can offset margin pressure, with bulls pointing to pricing power and possible fuel relief while bears worry about further earnings weakness.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is drawing attention amid a sharp semiconductor pullback and rebound, with traders debating whether AI infrastructure spending and debt-backed data-center expansion can generate adequate returns. Bearish concerns about financing and profitabilityespecially around CoreWeavecontrast with dip-buyers pointing to continued compute demand and Nvidias quantum-computing work.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Attention centers on AbCelleras ABCL635 Phase 2 data for menopausal hot flashes, with traders focused on whether conference updates add evidence on durability, safety and patient outcomes beyond the encouraging topline results. Bullish traders see the data as validation of the companys pipeline, while others caution that expectations may be high and the presentation could offer little new information or prompt profit-taking.

Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates

Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of +944.64% and +383.11%, respectively, for the quarter ended August 2026. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting

AbCellera (Nasdaq: ABCL) today announced an upcoming poster presentation of Phase 1/2 data on ABCL635 at The Menopause Societys (TMS) 2026 Annual Meeting, to be held October 20 to 24 at the Hilton Bayfront in San Diego, California. Details on AbCelleras poster presentation at TMS are as follows...

AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026

AbCellera (Nasdaq: ABCL) will announce its third quarter 2026 financial results on Monday, November 9, 2026, and hold an earnings conference call at 3:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will...

AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment

AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment AI Drug Discovery Forecasts Vary Widely as Sector Shifts to DeploymentPR NewswireAUSTIN, Texas, Oct. 1, 2026Equity Insider News CommentaryAUSTIN, Texas, Oct. 1, 2026 /PRNewswire/ --Towards Healthcare projects that the global AI...

Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today? 

Equity

The rallies were driven by expanding opportunities tied to biotechnology and artificial intelligence. 


Biotech And Biomimicry Stocks Lighting Up the Market

Biotech and life-science stocks are commanding attention as a fresh wave of momentum sweeps through the sector, with Silexion Therapeutics (NASDAQ:SLXN), Kraig Biocraft Laboratories (OTCQB:KBLB), 10x Genomics (NASDAQ:TXG), Moderna (NASDAQ:MRNA), AbCellera Biologics (NASDAQ:ABCL), Viatris (NASDAQ:VTRS), and Twist Bioscience (NASDAQ:TWST) among today’s notable names.

ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know

AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

AbCellera (Nasdaq: ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, to be held September 30 to October 3, 2026 at the Windsor Ocenico Hotel and Congress Center in Rio de Janeiro, Brazil...

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

AbCellera (Nasdaq: ABCL) announced that the Company will present at the Cantor Global Healthcare Conference on September 9, 2026. A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through...

What'sGoing On With AbCellera Biologics Stock On Tuesday?

AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals' FDA approval and the companies' antibody partnership.read more...

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Iovance shares hit a two-year high of $15.30 after the company raised its 2026 revenue forecast to $410 million-$420 million.</li><li>JPMorgan initiated coverage of AbCellera with an Overweight rating and $17 price target, citing promising ABCL635 data.&nbsp;</li><li>CrowdStrike shares hit a record $267.69 after the company announced plans to bring its Falcon platform to the OpenAI Marketplace.</li></ul>Iovance Biotherapeutics (<a class="mention" data-mention="$IOVA" data-symbol-id="IOVA" href="https://stocktwits.com/symbol/IOVA" target="_blank">IOVA</a>), AbCellera Biologics (ABCL) and CrowdStrike Holdings (CRWD) hit fresh 52-week highs on Tuesday as investors responded to stronger business outlooks, analyst support and AI-driven cybersecurity expansion.&nbsp;Iovance’s stock jumped 31%, while AbCellera and CrowdStrike stocks gained over 6% and 1%, respectively.&nbsp;<h2 class="st-heading-2">Iovance Biotherapeutics Raises Outlook</h2><a href="https://stocktwits.com/symbol/IOVA">Iovance stock</a> reached a two-year high of $15.30 after the biotech company raised its 2026 revenue outlook. The company now sees full-year sales between $410 million and $420 million, representing growth of almost 60% from last year and coming in well ahead of the consensus estimate of $407 million, according to Fiscal.ai data.The improved outlook reflects stronger commercial demand for Amtagvi, the company's tumor-infiltrating lymphocyte therapy for metastatic melanoma. The stronger business outlook also prompted H.C. Wainwright analyst Joseph Pantginis to lift his price target to $20 from $9 while keeping a ‘Buy’ rating.On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day.&nbsp;<h2 class="st-heading-2">AbCellera Gains JPMorgan Backing</h2><a href="https://stocktwits.com/symbol/ABCL">AbCellera stock</a> jumped to a four-year high of $15 as JPMorgan began covering the biotechnology company with an ‘Overweight’ rating and a $17 price target, describing the business as approaching a "major value inflection point."The firm pointed to clinical results from ABCL635, AbCellera's internal program targeting NK3R protein to address menopausal hot flashes. JPMorgan highlighted the candidate's combination of efficacy, safety, and dosing convenience.&nbsp;The firm also cited AbCellera's broad collection of pharmaceutical partnerships as support for its technology platform and noted that those relationships can help offset the company's operating expenses. Retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day.&nbsp;<h2 class="st-heading-2">CrowdStrike Expands Into OpenAI Marketplace</h2><a href="https://stocktwits.com/symbol/CRWD">CrowdStrike stock</a> climbed to a record high of $267.69 after the cybersecurity company announced plans to bring its Falcon platform to the OpenAI Marketplace.The move connects CrowdStrike's cloud-based security and threat intelligence capabilities with OpenAI's enterprise AI ecosystem. The integration will give business customers greater security while helping automate responses to potential threats. Investors expect the growing use of AI agents to increase demand for security tools.&nbsp;However, retail sentiment around the stock remained in ‘bearish’ territory.&nbsp;So far this year, <a class="mention" data-mention="$IOVA" data-symbol-id="IOVA" href="https://stocktwits.com/symbol/IOVA" target="_blank">IOVA</a>, ABCL and CRWD stocks have gained between 124% and 429%.Also see:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rum-stock-ticks-higher-overnight-analyst-sees-upside-as-13-billion-anthropic-deal-sets-off-ai-pivot/cZMnABwRBWV">RUM Stock Ticks Higher Overnight: Analyst Sees 94% Upside As $13B Anthropic Deal Sets Off AI Pivot</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the IOVANCE BIOTHERAPEUTICS logo is displayed on the screen of a tablet computer. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Iovance Biotherapeutics (IOVA), AbCellera Biologics (ABCL) and CrowdStrike Holdings (CRWD) hit fresh 52-week highs on Tuesday as investors responded to stronger business outlooks, analyst support and AI-driven cybersecurity expansion.

Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?

Crowdstrike Holdings Inc

iShares Genomics Immunology and Healthcare ETF

iShares Expanded Tech-Software Sector ETF

Iovance Biotherapeutics Inc

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$11.93
Prev Close	$11.80
Open	$12.05
Dividend Yield	0.00%
50-Day Moving Average	$12.02
Beta	1.72
Avg. Volume	4.6M
PE Ratio	-21.90

52-Week High	$15.02
52-Week Low	$2.75
Market Capitalization	$3.82B
EPS (Annual)	-$0.4901
Price to Book	4.08
Revenue Per Employee	$133,679.71

Feed

News

Sentiment

Earnings

Fundamentals

Info

ABCL Fundamentals